PRTK- Sarecycline looks like a NDA approval candidate shoo-in and Omadacycline a strong candidate. Allergan at the ready for marketing of Sarecycline (Acne Vulgaris market is fairly extensive) and my cursory read of the balance sheet looks pretty good. Market cap is low. All in all, I wish I had found this earlier, my money's been on TTPH in this space. Why this stock has slid down is puzzling. Did they dilute? The only other thing I caught was their website had the NDA for Omadacycline being submitted Q1, '18. Doesn't appear that they've met that deadline.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.